Merck scraps late-stage obesity drug taranabant
This article was originally published in Scrip
Executive Summary
Merck & Co has discontinued the Phase III development programme for its most advanced anti-obesity candidate taranabant (MK-0364) and will not seek regulatory approval for the drug this year as previously hoped, following concerns over safety of the drug at its higher, more effective doses.